GlassScriptPhysician profile
Daniel Bih-Chen Huang
NPI 1154427920
$41,550.44
in general payments reported to CMS, 2019-2025
100 companies · $7,957 in 2025
The $7,957 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,341 · 2020: $5,363 · 2021: $4,855 · 2022: $6,332 · 2023: $6,284 · 2024: $7,419 · 2025: $7,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Long Term Medical Supply Or Device Loan: $1,780 · Education: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,359.16 |
| Long Term Medical Supply Or Device Loan | $1,779.71 |
| Education | $520.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,726.76 | 2019-2025 | |
| Janssen Biotech, INC. | $2,759.05 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $2,071.11 | 2019-2025 | Imfinzi, Calquence, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $1,979.23 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Eisai INC. | $1,762.69 | 2019-2025 | |
| Incyte Corporation | $1,719.06 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $1,466.03 | 2019-2025 | |
| Verastem, INC. | $1,433.24 | 2019-2020 | |
| Celgene Corporation | $1,265.69 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| Glaxosmithkline, LLC. | $1,147.10 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Merck Sharp & Dohme LLC | $1,049.15 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $1,043.63 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $950.71 | 2019-2023 | Imbruvica, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $924.09 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
| Amgen INC. | $875.85 | 2019-2025 | Kyprolis, Nplate, Xgeva |
Show all 100 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $841.85 | 2019-2025 | |
| Astellas Pharma US INC | $789.41 | 2019-2025 | Xtandi, Padcev, Xospata |
| Puma Biotechnology, INC. | $770.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $707.00 | 2019-2025 | Gilotrif |
| Seagen INC. | $641.40 | 2020-2025 | Adcetris, Tukysa, Padcev |
| Regeneron Healthcare Solutions, INC. | $635.01 | 2019-2025 | Libtayo |
| Karyopharm Therapeutics INC. | $604.81 | 2020-2025 | Xpovio |
| Array Biopharma INC | $572.37 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Sobi, INC | $565.19 | 2021-2025 | |
| Daiichi Sankyo INC. | $529.58 | 2019-2025 | Enhertu, Datroway, Vanflyta |
| Genzyme Corporation | $490.77 | 2019-2025 | |
| Genentech USA, INC. | $490.22 | 2019-2025 | Phesgo, Polivy, Tecentriq |
| Emd Serono, INC. | $484.29 | 2019-2025 | Bavencio |
| Exelixis INC. | $470.54 | 2019-2025 | Cabometyx |
| Abbvie INC. | $458.65 | 2019-2025 | |
| Gilead Sciences, INC. | $438.26 | 2019-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $436.32 | 2019-2025 | Ultomiris |
| Beigene USA, INC. | $418.56 | 2022-2024 | Brukinsa |
| Csl Behring | $351.18 | 2019-2023 | Afstyla, Idelvion |
| Kite Pharma, INC. | $333.24 | 2020-2024 | Yescarta |
| Rigel Pharmaceuticals, INC. | $239.83 | 2020-2024 | Rezlidhia, Tavalisse |
| Myovant Sciences INC. | $213.17 | 2021-2022 | |
| Blueprint Medicines Corporation | $198.11 | 2020-2025 | Ayvakit |
| Sumitomo Pharma America, INC. | $197.66 | 2023-2025 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $190.13 | 2021-2025 | Fotivda |
| Agios Pharmaceuticals, INC. | $180.83 | 2020-2025 | Pyrukynd |
| Beone Medicines USA, INC. | $180.46 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $178.59 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $171.80 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
| Dendreon Pharmaceuticals LLC | $170.46 | 2019-2025 | Provenge |
| Pharmaessentia USA Corporation | $158.81 | 2023-2025 | Besremi |
| Adc Therapeutics America, INC. | $155.66 | 2022-2025 | |
| Springworks Therapeutics, INC. | $154.32 | 2024-2025 | Ogsiveo, Gomekli |
| Clovis Oncology, INC. | $150.93 | 2019-2020 | |
| Kyowa Kirin, INC. | $122.59 | 2021-2025 | Poteligeo |
| Eusa Pharma (US) LLC | $119.98 | 2019-2022 | |
| Octapharma USA, INC. | $117.12 | 2019-2022 | |
| Stemline Therapeutics INC. | $115.43 | 2023-2025 | Orserdu, Elzonris |
| Morphosys, US INC. | $115.10 | 2021-2024 | Monjuvi |
| Geron Corporation | $114.78 | 2025 | Rytelo |
| Stryker Corporation | $111.25 | 2023 | N/A |
| Cti Biopharma Corp. | $105.13 | 2022-2023 | Vonjo |
| Foundation Medicine, INC. | $91.49 | 2020-2023 | |
| Global Blood Therapeutics, INC. | $83.32 | 2020-2021 | |
| Coherus Oncology, INC. | $81.87 | 2024-2025 | Loqtorzi |
| Janssen Scientific Affairs, LLC | $76.94 | 2019-2023 | Darzalex, Imbruvica |
| Servier Pharmaceuticals LLC | $75.51 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $73.05 | 2023-2025 | Enjaymo, Sylvant |
| Mirati Therapeutics, INC. | $72.62 | 2023-2024 | Krazati |
| Epizyme, INC. | $70.27 | 2020-2022 | |
| Immunogen, INC. | $69.51 | 2023 | Elahere |
| Emmaus Medical, INC. | $62.98 | 2019-2023 | Endari |
| Apellis Pharmaceuticals, INC. | $61.47 | 2023-2024 | Empaveli |
| Sanofi-Aventis U.S. LLC | $57.04 | 2019-2020 | |
| Iovance Biotherapeutics, INC. | $55.32 | 2025 | Amtagvi |
| Tolmar Pharmaceuticals, INC. | $53.43 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $52.39 | 2021-2023 | Clonoseq |
| Secura Bio, INC. | $50.21 | 2020-2024 | Copiktra |
| Progenics Pharmaceuticals, INC. | $47.82 | 2024 | |
| Azurity Pharmaceuticals, INC. | $44.39 | 2025 | Danziten |
| Deciphera Pharmaceuticals INC. | $41.23 | 2021-2024 | Qinlock |
| Amag Pharmaceuticals, INC. | $41.00 | 2021 | |
| Novocure INC. | $38.71 | 2021-2022 | |
| Dova Pharmaceuticals | $35.52 | 2020 | |
| Partner Therapeutics, INC. | $34.76 | 2019-2020 | |
| Ge Healthcare | $34.52 | 2021-2025 | |
| Syndax Pharmaceuticals, INC. | $34.06 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $32.99 | 2023-2025 | Sancuso |
| Tesaro, INC. | $32.74 | 2019 | |
| Jazz Pharmaceuticals INC. | $29.45 | 2025 | |
| Baxter Healthcare | $28.81 | 2025 | Tisseel |
| Legend Biotech USA INC. | $27.63 | 2024 | |
| Alnylam Pharmaceuticals INC. | $27.60 | 2022 | |
| Aurobindo Pharma USA, INC. | $27.57 | 2020 | |
| Myriad Genetic Laboratories, INC. | $26.10 | 2021 | |
| Sun Pharmaceutical Industries INC. | $25.54 | 2019 | |
| Tersera Therapeutics LLC | $25.21 | 2025 | Zoladex |
| Acrotech Biopharma INC. | $24.77 | 2021 | |
| Mylan Institutional INC. | $24.24 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $19.93 | 2019 | |
| Accord Healthcare, INC. | $19.17 | 2023 | |
| Caris Mpi, INC. | $17.61 | 2025 | Mi Cancer Seek |
| Chiesi USA, INC. | $16.80 | 2023 | Ferriprox |
| Janssen Pharmaceuticals, INC | $15.21 | 2020 | |
| Optos, INC. | $14.21 | 2021 |
Drugs and devices associated with these payments
Kisqali $2,512Lenvima $934Darzalex $765Imbruvica $724Enhertu $550Opdivo $540Jaypirca $501Verzenio $496Imfinzi $482Keytruda $472Brukinsa $435Erleada $422Zejula $391Tecvayli $390Talvey $385Jemperli $367Jakafi $355Xtandi $354Calquence $336Padcev $326Doptelet $323Pomalyst $319Xpovio $318Libtayo $302Fruzaqla $292Orgovyx $274Scemblix $252Pluvicto $251Ojjaara $248Lynparza $240Mektovi $237Braftovi $237Fabhalta $228Nubeqa $228Gilotrif $221Ultomiris $220Stivarga $219Alunbrig $207Tivdak $199Opdualag $196Tagrisso $196Vitrakvi $194Cabometyx $194Tukysa $188Tavalisse $182Rezlidhia $182Talzenna $173Inlyta $169Lorbrena $166Rybrevant $165Besremi $159Adcetris $156Sarclisa $153Epkinly $153Akeega $152Balversa $148Monjuvi $148Piqray $146Vonjo $143Retevmo $140Pyrukynd $137Bosulif $135Reblozyl $128Iclusig $128Ayvakit $126Ibrance $122Ogsiveo $120Elrexfio $116Rytelo $115N/A $111Nerlynx $103Lonsurf $102Inqovi $102Trodelvy $101Orserdu $99.61Welireg $95.39Fotivda $91.83Elahere $90.85Ninlaro $89.48Xalkori $81.09Wayrilz $79.93Kyprolis $75.63Poteligeo $73.22Krazati $72.62Besponsa $68.17Zynlonta $64.64Phesgo $64.19Onivyde $64.12Mekinist $64.04Polivy $61.48Empaveli $61.47Amtagvi $55.32Udenyca $54.26Yescarta $53.54Tibsovo $51.67Venclexta $51.64Pylarify $47.82Xospata $47.68Danziten $44.39Pemazyre $41.50
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.